journal article·2026-07Open access

Tumor‐Derived Alpha‐1 Antitrypsin Promotes Liver Metastasis of Colorectal Cancer Through the Neutrophil Extracellular Traps–CCDC25 Pathway

Qian Fei, Chunning Li, Lei Zhan, Xiaoyan Li, Yan Hui, Yue Jin, Jing Zhang, Lu Yang, Xin Sun, Xiaoxi Li, Qian Dong, Jingdong Zhang

Advanced Science· Volume 13· Issue 39

Abstract

ABSTRACT Liver metastasis is a leading cause of mortality in colorectal cancer (CRC), where the inflammatory tumor microenvironment, specifically neutrophil infiltration, significantly promotes metastatic colonization. This study reveals a pro‐metastatic role for alpha‐1 antitrypsin (A1AT) in CRC liver metastasis via a dual mechanism involving neutrophil extracellular traps (NETs) and the transmembrane protein coiled‐coil domain‐containing protein 25 (CCDC25). We demonstrate that A1AT, highly expressed by a liver‐metastatic CRC cell line established in a mouse model, directly induces NETs’ formation. Simultaneously, intracellular A1AT binds to CCDC25, preventing its lysosomal degradation and thereby increasing its surface expression. This A1AT‐mediated upregulation of CCDC25 sensitizes tumor cells to surrounding NET–DNA. Upon engagement, the ILK–RAC1–CDC42 signaling cascade activates, driving extensive cytoskeletal rearrangement and enhancing the migratory and invasive capabilities of CRC cells. Collectively, our findings elucidate a mechanism wherein tumor cells exploit the A1AT–NET–CCDC25 axis to manipulate neutrophil function and boost metastatic potential. This axis represents a critical driver of CRC liver metastasis, offering novel biomarkers and promising therapeutic targets.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Neutrophil, Myeloperoxidase and Oxidative Mechanisms · Immune cells in cancer · Cell Adhesion Molecules Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Medical Oncology Department of Gastrointestinal Tumors Liaoning Key Laboratory of Gastrointestinal Cancer Translational Research Cancer Hospital of China Medical University Liaoning Cancer Hospital & Institute Cancer Hospital of Dalian University of Technology Shenyang China

Department of Oncology Shengjing Hospital of China Medical University Shenyang China

Central Laboratory Liaoning Key Laboratory of Gastrointestinal Cancer Translational Research Cancer Hospital of Dalian University of Technology Cancer Hospital of China Medical University Liaoning Cancer Hospital & Institute Shenyang China

Department of Pathology Cancer Hospital of China Medical University Liaoning Cancer Hospital & Institute Cancer Hospital of Dalian University of Technology Shenyang China

Oncology Department Chifeng Municipal Hospital/Chifeng Clinical College Inner Mongolia Medical University Chifeng China

Department of Oncology 6 The First Affiliated Hospital of Jinzhou Medical University Jinzhou China

References (49)

Show source-provided references
1. 10.1016/S0140‐6736(19)32319‐010.1016/S0140‐6736(19)32319‐0 ↗
2. 10.1186/s12967-025-06351-310.1186/s12967-025-06351-3 ↗
3. 10.1038/s41575-024-00934-z10.1038/s41575-024-00934-z ↗
4. 10.1016/j.stem.2015.05.01610.1016/j.stem.2015.05.016 ↗
5. 10.1186/s13578‐025‐01365‐210.1186/s13578‐025‐01365‐2 ↗
6. 10.3390/cancers1310241810.3390/cancers13102418 ↗
7. 10.1146/annurev‐pathol‐020712‐16402310.1146/annurev‐pathol‐020712‐164023 ↗
8. 10.1016/j.ccr.2011.08.01210.1016/j.ccr.2011.08.012 ↗
9. 10.1038/nature1440710.1038/nature14407 ↗
10. 10.1007/s00262‐016‐1921‐710.1007/s00262‐016‐1921‐7 ↗
11. 10.1186/s12967‐025‐07174‐y10.1186/s12967‐025‐07174‐y ↗
12. 10.1002/advs.20230261310.1002/advs.202302613 ↗
13. 10.1186/s13046‐024‐03244‐z10.1186/s13046‐024‐03244‐z ↗
14. 10.3389/fimmu.2021.78522210.3389/fimmu.2021.785222 ↗
15. 10.1016/j.cellsig.2025.11182210.1016/j.cellsig.2025.111822 ↗
16. 10.1172/JCI11273110.1172/JCI112731 ↗
17. 10.1126/scitranslmed.300711610.1126/scitranslmed.3007116 ↗
18. Update on Alpha‐1 Antitrypsin Deficiency in Liver Disease
19. 10.1002/hep.3277710.1002/hep.32777 ↗
20. 10.1016/S2213-2600(19)30056-610.1016/S2213-2600(19)30056-6 ↗
21. 10.1038/s41420‐024‐01990‐910.1038/s41420‐024‐01990‐9 ↗
22. 10.1016/S0002‐9440(10)65292‐310.1016/S0002‐9440(10)65292‐3 ↗
23. 10.1093/bioinformatics/btz21010.1093/bioinformatics/btz210 ↗
24. 10.1016/j.immuni.2020.03.00110.1016/j.immuni.2020.03.001 ↗
25. 10.1158/0008‐5472.CAN‐23‐298610.1158/0008‐5472.CAN‐23‐2986 ↗
26. 10.1084/jem.2010023910.1084/jem.20100239 ↗
27. 10.7150/jca.4421510.7150/jca.44215 ↗
28. 10.1126/scitranslmed.aag171110.1126/scitranslmed.aag1711 ↗
29. 10.1016/S0021‐9258(19)61505‐X10.1016/S0021‐9258(19)61505‐X ↗
30. 10.3389/fimmu.2024.144329710.3389/fimmu.2024.1443297 ↗
31. 10.1038/s41586‐020‐2394‐610.1038/s41586‐020‐2394‐6 ↗
32. 10.1016/j.ccr.2013.08.01210.1016/j.ccr.2013.08.012 ↗
33. 10.1016/j.rmed.2011.02.00210.1016/j.rmed.2011.02.002 ↗
34. 10.1056/NEJM19990211340060710.1056/NEJM199902113400607 ↗
35. 10.1158/0008‐5472.CAN‐11‐387310.1158/0008‐5472.CAN‐11‐3873 ↗
36. 10.1093/jnci/dju12410.1093/jnci/dju124 ↗
37. 10.1038/s41598‐019‐56218‐z10.1038/s41598‐019‐56218‐z ↗
38. 10.3390/cancers1323613110.3390/cancers13236131 ↗
39. 10.1016/j.immuni.2021.01.01210.1016/j.immuni.2021.01.012 ↗
40. 10.2147/JHC.S30358810.2147/JHC.S303588 ↗
41. 10.1111/cas.1315610.1111/cas.13156 ↗
42. 10.3389/fimmu.2019.0208810.3389/fimmu.2019.02088 ↗
43. 10.1038/s41598‐017‐06893‐710.1038/s41598‐017‐06893‐7 ↗
44. 10.1002/JLB.3A0120‐050RR10.1002/JLB.3A0120‐050RR ↗
45. 10.1155/2023/702233710.1155/2023/7022337 ↗
46. 10.3390/biom1203038010.3390/biom12030380 ↗
47. 10.1165/ajrcmb.26.6.473910.1165/ajrcmb.26.6.4739 ↗
48. 10.3892/ol.2017.644610.3892/ol.2017.6446 ↗
49. 10.1096/fj.202301064RR10.1096/fj.202301064RR ↗